OTCMKTS:MRMD MariMed (MRMD) Stock Price, News & Analysis $0.17 0.00 (0.00%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get MariMed alerts: Email Address About MariMed Stock (OTCMKTS:MRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MariMed alerts:Sign Up Key Stats Today's Range$0.17▼$0.1850-Day Range$0.15▼$0.2852-Week Range$0.14▼$0.46Volume287,614 shsAverage Volume455,047 shsMarket Capitalization$64.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.Read More… Jovine Was Right in 2008—Will You Listen This Time? (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW MariMed Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks10th Percentile Overall ScoreMRMD MarketRank™: MariMed scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MariMed.Read more about MariMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of MariMed is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MariMed is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMariMed has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the outstanding shares of MariMed have been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently increased by 77.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMariMed does not currently pay a dividend.Dividend GrowthMariMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the outstanding shares of MariMed have been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently increased by 77.52%, indicating that investor sentiment is decreasing significantly. News and Social Media0.8 / 5News Sentiment-0.50 News SentimentMariMed has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MariMed this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MRMD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added MariMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MariMed insiders have not sold or bought any company stock.Percentage Held by Insiders20.55% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.18% of the stock of MariMed is held by institutions.Read more about MariMed's insider trading history. Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address MRMD Stock News HeadlinesMariMed Commences Adult-Use Sales at Thrive Wellness Dispensary in Tiffin, OhioSeptember 24, 2024 | globenewswire.comMariMed’s Bubby’s Baked Introduces New, Limited-Edition Pumpkin Bread Bites This AutumnSeptember 10, 2024 | markets.businessinsider.comFDA’s hidden signal greenlights biotech winners — 97% of the timeThe FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow.September 28, 2024 | Weiss Ratings (Ad)Key Cannabis Leaders Gather For Networking At Benzinga's Fall 2024 Conference: The Last Big Event Before The ElectionAugust 26, 2024 | msn.comMariMed Inc. (MRMD.CN)August 23, 2024 | uk.finance.yahoo.comMariMed Announces Opening of Second Maryland DispensaryAugust 19, 2024 | globenewswire.comVerano, Green Thumb & MariMed's Strong Q2: Unpacking The Cannabis Earnings SurgeAugust 16, 2024 | benzinga.comCanadian Securities Exchange (CSE): Canadian Securities Exchange Reports July 2024 Performance FiguresAugust 14, 2024 | finanznachrichten.deSee More Headlines MRMD Stock Analysis - Frequently Asked Questions How have MRMD shares performed this year? MariMed's stock was trading at $0.2748 at the beginning of 2024. Since then, MRMD stock has decreased by 38.1% and is now trading at $0.17. View the best growth stocks for 2024 here. How were MariMed's earnings last quarter? MariMed Inc. (OTCMKTS:MRMD) announced its earnings results on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The business earned $33.21 million during the quarter. MariMed had a negative trailing twelve-month return on equity of 2.75% and a negative net margin of 10.97%. How do I buy shares of MariMed? Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MariMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that MariMed investors own include KushCo (KSHB), Organigram (OGI), Auxly Cannabis Group (CBWTF), CNBX Pharmaceuticals (CNBX), Supreme Cannabis (SPRWF), Pennsylvania Real Estate Investment Trust (PEI). Company Calendar Last Earnings11/15/2021Today9/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:MRMD CUSIPN/A CIK1522767 Webmarimedadvisors.com Phone(617) 795-5140FaxN/AEmployees260Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,030,000.00 Net Margins-10.97% Pretax Margin-5.28% Return on Equity-2.75% Return on Assets-1.06% Debt Debt-to-Equity Ratio1.01 Current Ratio1.55 Quick Ratio0.73 Sales & Book Value Annual Sales$148.60 million Price / Sales0.43 Cash Flow$0.03 per share Price / Cash Flow5.59 Book Value$0.19 per share Price / Book0.89Miscellaneous Outstanding Shares379,671,000Free Float301,649,000Market Cap$64.54 million OptionableNot Optionable Beta2.80 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:MRMD) was last updated on 9/28/2024 by MarketBeat.com Staff From Our PartnersWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Hua...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MariMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MariMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.